Cardiology: A Big-hearted Molecule

Overview

Journal Nature

Specialty Science

Date 2015 Mar 25

PMID 25799985

Citations 4

Authors

Michaela Kuhn

Affiliations

Soon will be listed here.

Citing Articles

Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development.

Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R Rev Cardiovasc Med. 2024; 23(5):165.

PMID: 39077592 PMC: 11273913. DOI: 10.31083/j.rcm2305165.

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).

PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.

Electrochemical Detection of NT-proBNP Using a Metalloimmunoassay on a Paper Electrode Platform.

Pollok N, Rabin C, Walgama C, Smith L, Richards I, Crooks R ACS Sens. 2020; 5(3):853-860.

PMID: 32154707 PMC: 7103555. DOI: 10.1021/acssensors.0c00167.

cUMP hydrolysis by PDE3A.

Berrisch S, Ostermeyer J, Kaever V, Kalble S, Hilfiker-Kleiner D, Seifert R Naunyn Schmiedebergs Arch Pharmacol. 2016; 390(3):269-280.

PMID: 27975297 DOI: 10.1007/s00210-016-1328-1.

References

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

Maurice D, Ke H, Ahmad F, Wang Y, Chung J, Manganiello V . Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014; 13(4):290-314. PMC: 4155750. DOI: 10.1038/nrd4228. View

Holtwick R, van Eickels M, Skryabin B, Baba H, Bubikat A, Begrow F . Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003; 111(9):1399-407. PMC: 154444. DOI: 10.1172/JCI17061. View

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

McMurray J, Packer M, Desai A, Gong J, Lefkowitz M, Rizkala A . Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11):993-1004. DOI: 10.1056/NEJMoa1409077. View

Takimoto E, Champion H, Li M, Belardi D, Ren S, Rodriguez E . Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11(2):214-22. DOI: 10.1038/nm1175. View

Lee D, Zhu G, Sasaki T, Cho G, Hamdani N, Holewinski R . Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519(7544):472-6. PMC: 4376609. DOI: 10.1038/nature14332. View

Frantz S, Klaiber M, Baba H, Oberwinkler H, Volker K, GaBner B . Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J. 2011; 34(16):1233-44. PMC: 3631523. DOI: 10.1093/eurheartj/ehr445. View

Ehret G, Munroe P, Rice K, Bochud M, Johnson A, Chasman D . Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478(7367):103-9. PMC: 3340926. DOI: 10.1038/nature10405. View

10.

Kuhn M . Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res. 2003; 93(8):700-9. DOI: 10.1161/01.RES.0000094745.28948.4D. View

11.

Zakeri R, Burnett J . Designer natriuretic peptides: a vision for the future of heart failure therapeutics. Can J Physiol Pharmacol. 2011; 89(8):593-601. DOI: 10.1139/y11-048. View

12.

Ampadu J, Morley J . Heart failure and cognitive dysfunction. Int J Cardiol. 2014; 178:12-23. DOI: 10.1016/j.ijcard.2014.10.087. View